HPV Vaccination: Broader Implementation and Development of Next-Generation Vaccines Reduce the Incidence of Cervical Cancer

Year : 2026 | Volume : 16 | Issue : 01 | Page : 11 20
    By

    Saeeda Wasim,

  • Sharique Ahmad,

  • Sonya Kamegni Mombo Nkonda,

  • Rokib Hasan Morad,

  • Ethelbert Olisaemeka Okwaranyia,

  • Subuhi Anwar,

  1. Senior Consultant, Nova IVF Infertility, Hazratganj, Lucknow, Uttar Predesh, India
  2. Professor, Department of Pathology, Era’s Lucknow Medical College and Hospital, Lucknow, Uttar Pradesh, India
  3. Student, Department of Medicine, American University of Barbados School of Medicine, Wildey, Bridgetown, Saint Michael, BB-11100, Barbados
  4. Student, Department of Medicine, American University of Barbados School of Medicine, Wildey, Bridgetown, Saint Michael, BB-11100, Barbados
  5. Student, Department of Medicine, American University of Barbados School of Medicine, Wildey, Bridgetown, Saint Michael, BB-11100, Barbados
  6. Research Assistant, Department of Pathology, Era’s Lucknow Medical College and Hospital, Lucknow, Uttar Pradesh, India

Abstract

Cervical cancer has been an important health issue of global concern which has almost universally been fuelled by the persistent infection of high-risk Human Papillomavirus (HPV). The most effective way of primary prevention is prophylactic HPV vaccination. The extensive real-world evidence obtained through national immunization programs throughout the world has given unambiguous evidence of the effect of the vaccine as a decline in the incidence of high-grade cervical pre-cancers and more importantly a reduction of risk of invasive cervical cancer (ICC) in cohorts vaccinated at a young age of adolescence. To achieve the elimination goals identified by World Health Organization (WHO) global efforts are progressively focusing on highly effective simplified strategies especially the introduction of a single-dose schedule, which is supported by long-term follow-up studies. The advent of the cheap locally produced vaccines and concomitant governmental promises in high-burden situations is a watershed turning point to overcome the historical obstacles of price and availability. The future research is aimed at next generation vaccines, such as broad spectrum L2 based vaccines and therapeutic platforms, which are likely to increase coverage and shorten logistics in distributing the vaccine, thus hastening the global initiative to end cervical cancer. This venture will only succeed with the help of the political will that is going to be maintained, the fair access, as well as the implementation of both primary and secondary preventive measures.

Keywords: Cervical cancer, global health, HPV vaccination, human papillomavirus, next-generation vaccines

[This article belongs to Research and Reviews : A Journal of Immunology ]

How to cite this article:
Saeeda Wasim, Sharique Ahmad, Sonya Kamegni Mombo Nkonda, Rokib Hasan Morad, Ethelbert Olisaemeka Okwaranyia, Subuhi Anwar. HPV Vaccination: Broader Implementation and Development of Next-Generation Vaccines Reduce the Incidence of Cervical Cancer. Research and Reviews : A Journal of Immunology. 2026; 16(01):11-20.
How to cite this URL:
Saeeda Wasim, Sharique Ahmad, Sonya Kamegni Mombo Nkonda, Rokib Hasan Morad, Ethelbert Olisaemeka Okwaranyia, Subuhi Anwar. HPV Vaccination: Broader Implementation and Development of Next-Generation Vaccines Reduce the Incidence of Cervical Cancer. Research and Reviews : A Journal of Immunology. 2026; 16(01):11-20. Available from: https://journals.stmjournals.com/rrjoi/article=2026/view=238565


References

  1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.
  2. Walboomers JMM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12–19.
  3. Schiffman M, Wacholder S, Wheeler CM. Human papillomavirus vaccine: The first 10 years. Lancet. 2016;388(10042):427–430.
  4. Bavdekar A, Bhave S, Sharma A, et al. Safety and immunogenicity of a bivalent and a quadrivalent HPV vaccine in healthy Indian adolescent girls. Pediatr Infect Dis J. 2017;36(1):108–115.
  5. World Health Organization (WHO). Global strategy to accelerate the elimination of cervical cancer as a public health problem. Geneva: WHO; 2020.
  6. Gavi, The Vaccine Alliance. HPV vaccine: State of the art and novel approaches. 2024. Available from: https://www.gavi.org/.
  7. Jansen KU, Shaw AR. Human papillomavirus vaccines and prevention of cervical cancer. Annu Rev Med. 2004;55:319–331.
  8. Kitchener HC, Canfell K, Brotherton JML, et al. Long-term protection from human papillomavirus vaccination. Vaccine. 2024;42(1):1–8.
  9. Falcaro M, Castanon A, Ndlela B, et al. The effects of the national HPV vaccination programme in England on cervical cancer and invasive cervical neoplasia: A population-based observational study. Lancet. 2021;397(10290):1979–1987
  10. Lei J, Ploner C, Elfström KM, et al. HPV vaccination and the risk of invasive cervical cancer. N Engl J Med. 2020;383(16):1589–1597
  11. Palmer T, Wallace L, Pollock KG, et al. Prevalence of cervical disease at age 20 after implementation of the HPV vaccination programme in Scotland: Retrospective population study. BMJ. 2019;365:l1161.
  12. Drolet M, Bénard É, Pérez N, et al. Population-level impact and herd effects of the human papillomavirus (HPV) vaccine: A systematic review and meta-analysis. Lancet. 2015;385(9963):141–151.
  13. World Health Organization (WHO). Human papillomavirus (HPV) vaccines: WHO position paper, December 2022. Wkly Epidemiol Rec. 2022;97(50):645–662.
  14. Joshi S, Anantharaman D, Muwonge R, et al. Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-years post-vaccination. Vaccine. 2023;41(1):236–245.
  15. Meijers MK, de Melker HE, van Santen J, et al. Modeling the impact of a one-dose vs two-dose HPV vaccination schedule in the Netherlands. Vaccine. 2023;41(1):246–255.
  16. World Health Organization (WHO). WHO HPV vaccination coverage estimates. Geneva: WHO; 2024.
  17. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
  18. Sankaranarayanan R, Muwonge R, Kumaraswamy IP, et al. HPV infection in women in India: An evidence based perspective. J Indian Med Assoc. 2012;110(3):146–150, 152.
  19. Bhatla N, Dar L, Mallika V, et al. Challenges and opportunities to making Indian women cervical cancer free. J Obstet Gynaecol India. 2024;74(1):22–30.
  20. Gupta A, Singh S. Current status & impact of human papillomavirus vaccination: Implications for India. Indian J Med Res. 2016;143(5):543–552.
  21. Evaluation of the HPV vaccine in India. Seattle, WA: PATH; 2010.
  22. Gupta M, Singh H, Boparai V, et al. Barriers to HPV vaccination in India: A systematic review. Indian J Public Health. 2019;63(2):107–113.
  23. Arora A, Bano S, Mittal R, et al. Understanding human papillomavirus vaccination practices among women in South Delhi: Insights from a tertiary care center. J Med Sci. 2025; [Epub ahead of print].
  24. Sreedharan J, Somanath S, Sreekumari C, et al. Knowledge, attitude and practice on HPV vaccine among college girls in Coastal Karnataka, India. Indian J Sex Transm Dis AIDS. 2016;37(2):162–167.
  25. Prabakaran D, Gajalakshmi V, Kanimozhi C, et al. Accelerating cervical cancer elimination in India: Challenges and way forward. Lancet Oncol. 2024;25(4):e185–e192.
  26. Serum Institute of India (SII). CERVAVAC: India’s first indigenous qHPV vaccine. Pune, India: SII; 2023.
  27. Jain R, Chatterjee C, Bandyopadhyay S, et al. Immunogenicity and safety of an indigenous quadrivalent HPV vaccine in Indian adolescent girls: A phase II/III randomized controlled trial. JAMA Oncol. 2022;8(10):1495–1503.
  28. Chauhan AS, Mittal R, Sharma A, et al. Cost-effectiveness analysis of introducing the indigenous quadrivalent HPV vaccine (CERVAVAC) into India’s national immunization program. Vaccine. 2023;41(2):345–352.
  29. Ministry of Health and Family Welfare (MoHFW), Government of India. Press release on HPV vaccination in the Union Budget 2024. New Delhi: MoHFW; 2024.
  30. Nundy S, Barua S, Nundy K. India prepares to introduce HPV vaccine in national immunization program. HPV World. 2024; [Epub ahead of print].
  31. Bhatla N, Denny L, Gravitt PE, et al. HPV vaccination in the elimination of cervical cancer. Int J Gynaecol Obstet. 2021;152(Suppl 1):74–81.
  32. Joura EA, Giuliano AR, Iversen ME, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711–723
  33. Li Y, Bi D, Hu Z, et al. A novel pan-HPV prophylactic L2 vaccine. 2022;40(10):1494–1500.
  34. Pastrana DV, Gambhira R, Buck CB, et al. Human papillomavirus L2: The long-sought universal vaccine candidate. Expert Rev Vaccines. 2010;9(3):283–294.
  35. Schellenbacher C, Gumpenberger T, Janzek E, et al. A L2-based human papillomavirus vaccine cocktail with broad protection against oncogenic HPV types. J Infect Dis. 2017;215(3):410–417.
  36. Jurgens-Boronowicz J, Boudreau T, Smith J, et al. Current status and future directions for the development of human papillomavirus vaccines. Front Immunol. 2024;15:1362770.
  37. Bryan J, Gissmann L, Gissmann L, et al. The HPV vaccine – development, current use and efficacy. Int J Clin Pharm Res. 2007; [Epub ahead of print].
  38. Stanley M. HPV vaccination: Progress and challenges. 2020;38(49):7789–7793.
  39. Gavi, The Vaccine Alliance. HPV: The next generation of vaccines. 2024. Available from: https://www.gavi.org/.
  40. Bender N, Stitz J, Jochner N, et al. Therapeutic HPV E6/E7 mRNA vaccination in combination with PD-1 inhibition in preclinical models. 2023;12(1):2171286.
  41. Pardi N, Hogan MJ, Weissman D. mRNA vaccines — A new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261–279.
  42. Kaufman HL, Trimble CL, Paavonen J, et al. Efficacy and safety of a virus-like particle therapeutic vaccine in women with high-grade cervical intraepithelial neoplasia: A randomized, phase 2b, multicentre, double-blind, placebo-controlled trial. Lancet Oncol. 2020;21(3):395–405
  43. Russo V, Lamberti M, Baldi M, et al. Advances in therapeutic human papillomavirus vaccines. 2021;39(28):3677–3687.
  44. Doorbar J, Gallimore A, Roberts S, et al. The E6 and E7 oncogenes of high-risk HPV: Targets for therapeutic intervention. Future Oncol. 2006;2(4):463–472.
  45. Bodey AJ, Latini A, Ma B, et al. Therapeutic vaccines for human papillomavirus-induced malignancy. Vaccines (Basel). 2021;9(5):492.
  46. Dadar M, Chakraborty S, Dhama K, Prasad M, Khandia R, Hassan S, Munjal A, Tiwari R, Karthik K, Kumar D, Iqbal HM. Advances in designing and developing vaccines, drugs and therapeutic approaches to counter human papilloma virus. Frontiers in immunology. 2018 Nov 12;9:2478.
  47. Tosti G, Fregoni S, Nencioni A, et al. Immunotherapy for HPV-related cancers: Current status and future perspectives. Cancers (Basel). 2021;13(4):872.
  48. Tjalma WA, Arbyn M, Paavonen J, Van Waes TR, Bogers JJ. Prophylactic human papillomavirus vaccines: the beginning of the end of cervical cancer. International Journal of Gynecological Cancer. 2004 Aug 1;14(5):751-61.
  49. Wu S, Ploner A, Alsina AM, Deng Y, Schollin LA, Lei J. Effectiveness of quadrivalent human papillomavirus vaccination against high-grade cervical lesions by age and doses: a population-based cohort study. The Lancet Regional Health–Europe. 2025 Feb 1;49.
  50. Kemp T, Kjær SK, Jensen MA, et al. Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four Nordic countries. 2020;38(49):7733–7742.
  51. Bonjour M, Charvat H, Franco EL, Pineros M, Clifford GM, Bray F, Baussano I. Global estimates of expected and preventable cervical cancers among girls born between 2005 and 2014: a birth cohort analysis. The Lancet Public Health. 2021 Jul 1;6(7):e510-21.
  52. Henschke N, Bergman H, Adewuyi EO, et al. HPV vaccination reduces risk of cervical cancer: Two new Cochrane reviews provide clear and consistent evidence. 2025;391:r2479.
  53. Joshi S, Anantharaman D, Muwonge R, et al. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: A multicentre, prospective, cohort study. Lancet Oncol. 2023;24(1):50–59.
  54. Herweijer E, Sundström K, Ploner A, Uhnoo I, Sparén P, Arnheim‐Dahlström L. Quadrivalent HPV vaccine effectiveness against high‐grade cervical lesions by age at vaccination: a population‐based study. International journal of cancer. 2016 Jun 15;138(12):2867-74.
  55. Crowe E, Pandeya N, Brotherton JM, Dobson AJ, Kisely S, Lambert SB, Whiteman DC. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. Bmj. 2014 Mar 4;348.
  56. Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, Bartholomew D, Cestero RM, Fedrizzi EN, Hirschberg AL, Mayrand MH. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial. The Lancet. 2017 Nov 11;390(10108):2143-59.
  57. Baldur-Felskov B, Dehlendorff C, Munk C, Kjaer SK. Early impact of human papillomavirus vaccination on cervical neoplasia—nationwide follow-up of young Danish women. Journal of the National Cancer Institute. 2014 Mar 1;106(3):djt460.
  58. Arbyn M, Xu L, Simms K, et al. The clinical efficacy and effectiveness of human papillomavirus (HPV) vaccines: A systematic review and meta-analysis. 2018;36(32):4503–4517.
  59. Van Damme P, Meijer CJ, Kieninger D, Schuyleman A, Thomas S, Luxembourg A, Baudin M. A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in men. 2016 Jul 29;34(35):4205-12.
  60. Spinner C, Ding L, Bernstein DI, Brown DR, Franco EL, Covert C, Kahn JA. Human papillomavirus vaccine effectiveness and herd protection in young women. Pediatrics. 2019 Feb 1;143(2):e20181902.
  61. Davies-Oliveira JC, Smith MA, Grover S, Canfell K, Crosbie EJ. Eliminating cervical cancer: progress and challenges for high-income countries. Clinical Oncology. 2021 Sep 1;33(9):550-9.
  62. Sherris JD, Wittet S, Danon K, et al. Monitoring the introduction of human papillomavirus vaccines in developing countries. 2008;26(28):3430–3434.
  63. Jain N, Singh R, Choudhury M, et al. The challenge of HPV vaccination in India: An economic perspective. Indian J Med Res. 2020;151(1):50–58.
  64. Chaurasia A, Kedia D, Patave M, et al. Implementation of school-based HPV vaccination programs in India: A systematic review and meta-analysis of pilot projects. Int J Gynaecol Obstet. 2021;155(3):477–485.
  65. Fisher H, Drolet M, Kwong JC, et al. HPV vaccination uptake and the influence of information sources: A systematic review and meta-analysis. Lancet Public Health. 2023;8(6):e460–e470.
  66. Basu P, Batra P, Kothari A, et al. Efficacy of one-dose versus two-dose versus three-dose of quadrivalent HPV vaccine in girls aged 10-18 years in India: A multi-centre, open-label, randomized controlled trial. 2024;42(1):9–16.
  67. Canfell K, Zhao F, Kuo Y, et al. WHO cervical cancer elimination goals and HPV vaccination: Impact of moving to a two-dose or one-dose schedule. Int J Cancer. 2024;155(2):236–246.
  68. Rodríguez-Cerdeira C, Sánchez-Blanco MP, Sánchez-Blanco E, et al. New therapeutic and prophylactic vaccines against human papillomavirus. Int J Mol Sci. 2021;22(22):12185.
  69. De Visi F, Hotez PJ, Serghides L. Making HPV vaccines globally accessible and affordable: Lessons from low-cost vaccine development and implementation. 2020;38(49):7794–7798.
Regular Issue Subscription Review Article
Volume 16
Issue 01
Received 07/02/2026
Accepted 07/02/2026
Published 16/03/2026
Publication Time 37 Days
39

Login


My IP

PlumX Metrics